Safety and efficacy of off-label bulevirtide monotherapy in HDV patients with decompensated Child-B cirrhosis – a real world case series

Christopher Dietz-Fricke,Elisabetta Degasperi,Mathias Jachs,Benjamin Maasoumy,Florian P. Reiter,Andreas Geier,Julia M. Grottenthaler,Christoph P. Berg,Kathrin Sprinzl,Stefan Zeuzem,Juliana Gödiker,Bernhard Schlevogt,Toni Herta,Johannes Wiegand,Roberta Soffredini,Heiner Wedemeyer,Katja Deterding,Thomas Reiberger,Pietro Lampertico

DOI: https://doi.org/10.1097/hep.0000000000000847

IF: 17.298

2024-03-13

Hepatology

Abstract:Background & Aims: Chronic hepatitis D is the most debilitating form of viral hepatitis frequently progressing to cirrhosis and subsequent decompensation. However, the HDV entry inhibitor bulevirtide is only approved for antiviral treatment of patients with compensated disease. We aimed for the analysis of real-world data on the off-label use of bulevirtide in the setting of decompensated liver cirrhosis. Approach & Results: We conducted a retrospective study in HDV-patients with decompensated liver disease at German, Austrian and Italian centers. We included 19 patients (47% male, mean age: 51 y) with liver cirrhosis Child-Pugh B. Median MELD score was 12 (range 9-17) at treatment initiation. Median observation period was 41 weeks. Virologic response was achieved in 74% and normal ALT was observed in 74%. Combined response was achieved by 42%. The most relevant adverse events included self-limited ALT flares, an asymptomatic increase in bile acids and need for liver transplantation. Despite bile acid increases adverse events were considered unrelated. Clinical and laboratory improvement from Child-Pugh B to A occurred in 47% (n=9/19). Improvements in the amount of ascites were observed in 58% of patients initially presenting with ascites (n=7/12). Conclusions: This report on off-label bulevirtide treatment in patients with decompensated HDV cirrhosis shows similar virologic and biochemical response rates as observed in compensated liver disease. Significant improvements were observed on surrogates of hepatic function and portal hypertension. However, this improvement was not seen in all patients. Controlled trials are needed to confirm safety and efficacy of bulevirtide in decompensated HDV-cirrhosis.

gastroenterology & hepatology